All sponsors

3D Medicines (Sichuan) Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING4
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO100%

Delay Index: of 6 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +48.0 months). See all sponsors →

Open 3D Medicines (Sichuan) Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Lenvatinib + Envafolimab
NCT05024214
P1/2RecruitingSolid Tumors; Non-small Cell Lung Cancer1702026-12 (+38 mo)
Envafolimab+Lenvatinib
NCT05112991
P2RecruitingAdvanced Endometrial Cancer1082026-12 (+35 mo)
KN035
NCT03667170
P2Active, not recruitingSolid Tumor1882026-12-30 (+90 mo)
Envafolimab
NCT04891198
P2RecruitingSolid Tumor1262027-08-30 (+58 mo)
Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
NCT06123754
P3RecruitingNon-small Cell Lung Cancer3902027-12-30 (+24 mo)
Envafolimab plus Gemcitabine&Cisplatin
NCT04910386
P2Not yet recruitingBiliary Tract Neoplasms1262029-06 (+48 mo)